# Dose-Escalating Study Of SB-485232 Administered Intravenously Every 28 Days To Adults With Solid Tumors Or Lymphomas

> **NCT00085904** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 12 (actual)

## Conditions studied

- Solid Tumor Cancer
- Lymphoma

## Interventions

- **DRUG:** SB-485232

## Key facts

- **NCT ID:** NCT00085904
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2008-10-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00085904

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00085904, "Dose-Escalating Study Of SB-485232 Administered Intravenously Every 28 Days To Adults With Solid Tumors Or Lymphomas". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00085904. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*